Siga (SIGA)

Executive Summary

SIGA Technologies is a commercial-stage biopharmaceutical company dedicated to addressing serious infectious diseases, particularly orthopoxviruses. Its lead product, TPOXX (tecovirimat), is the only FDA-approved antiviral for smallpox and is also used under emergency authorization for mpox (monkeypox). With a focus on bioterrorism preparedness and global outbreak response, SIGA has established TPOXX as a critical component of the U.S. Strategic National Stockpile and has secured multiple procurement contracts. The company's approved status and revenue-generating product provide a strong commercial foundation, while its pipeline explores expanded indications and formulations to broaden its reach.

Upcoming Catalysts (preview)

• Q4 2026Pediatric approval for TPOXX (oral suspension or IV formulation)75% success
• Q3 2026BARDA procurement contract renewal or expansion80% success
• Q2 2027Regulatory approval for TPOXX in mpox (monkeypox) indication60% success